Q-omics provides the consensus-scored KRT7-AS profile across patient tissues and cancer cell-line models. KRT7-AS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KRT7-AS is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KRT7-AS RNA expression shows 16,356 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where KRT7-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT7-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT7-AS survival associations across molecular data types. KRT7-AS RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT7-AS RNA expression–survival associations across cancer types. High KRT7-AS expression shows unfavorable associations in UCEC, UVM, OV, LGG and THCA, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KRT7-AS RNA expression.
This table summarizes KRT7-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT7-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT7-AS shows lower tumor expression in KIRC, LUSC, BRCA and HNSC and higher tumor expression in COAD and STAD. The KIRC box plot shows higher KRT7-AS RNA expression in normal versus tumor tissue (log2 FC = −0.753, t-test p < 0.001).
This table shows molecular features associated with KRT7-AS in patient tissues and cancer cell lines. In patient samples, KRT7-AS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
